A new publication dated September 15, 2026, reports on insulin degludec in combination with liraglutide. The study, titled "Real-world treatment-transition pathways and dosing patterns of insulin degludec/liraglutide in Chinese adults with type 2 diabetes," appeared in the journal Metabolism Open. The publication is indexed under PubMed ID 42857180. It focuses on real-world treatment-transition pathways and dosing patterns among adults with type 2 diabetes in China. No specific findings or outcomes beyond the study title and focus have been disclosed in this listing. Insulin degludec remains an approved compound, and this publication adds to the body of literature examining its real-world use in combination therapy. Readers interested in the broader context of insulin degludec, including its regulatory status and other published research, can consult the compound overview for additional background.
New Publication on Insulin Degludec/Liraglutide Treatment Patterns
See the full insulin degludec overview
Source: https://pubmed.ncbi.nlm.nih.gov/42857180/